Immucept 250/Immucept 500

Immucept 250/Immucept 500

mycophenolic acid


Intas Pharmaceuticals


Berlin Pharm


Berlin Pharm
Concise Prescribing Info
Mycophenolate mofetil
Prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants in combination w/ ciclosporine & corticosteroids. Refractory acute transplant rejection in patients receiving allogeneic renal. Induction & maintenance therapy in patients w/ class III-IV lupus nephritis.
Dosage/Direction for Use
Renal transplant Adult 1 g bid initiated w/in 72 hr following transplantation. Childn & adolescents 2-18 yr 600 mg/m2 bid. Max: 2 g daily. BSA 1.25-1.5 m2 750 mg bid (1.5 g daily dose), >1.5 m2 1 g bid (2 g daily dose). Elderly ≥65 yr 1 g bid. Cardiac transplant Adult 1.5 g bid (3 g daily dose). Elderly ≥65 yr 1.5 g bid. Hepatic transplant Adult 1.5 g bid (3 g daily dose). Elderly ≥65 yr 1.5 g bid. Lupus nephritis Induction therapy: 750 mg to 1.5 g bid (up to 3 g daily dose). Maintenance therapy: 500 mg to 1 g bid (2 g daily dose).
May be taken with or without food: In stable renal transplant patients, may be administered w/ meals if necessary.
Hypersensitivity to mycophenolate mofetil, mycophenolic acid. Lactation.
Special Precautions
Increased risk of developing lymphomas & other malignancies, risk for opportunistic infections (bacterial, fungal, viral & protozoal), fatal infections & sepsis. Limit exposure to sunlight or UV light. Monitor patients for neutropenia & ensure to have CBC wkly during the 1st mth, twice mthly for 2nd & 3rd mth of treatment, then mthly through the 1st yr. Pure red cell aplasia (PRCA). Avoid use of live attenuated vaccines & w/ rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) eg, Lesch-Nyhan & Kelley-Seegmiller syndrome. Patients w/ active serious digestive system disease. Pregnancy.
Adverse Reactions
Diarrhea, leukopenia, sepsis & vomiting. Lymphomas & other malignancies; candida mucocutaneous, CMV viraemia/syndrome & herpes simplex; abdominal pain, anemia, fever, HTN, infection, pain, pharyngitis, resp tract infection; GI haemorrhage, pulmonary oedema.
Drug Interactions
Increase plasma conc of acyclovir, ganciclovir, valacyclovir. Decreased absorption w/ antacids (Mg & Al hydroxides). Potential reduction of efficacy w/ cholestyramine & drugs that interfere w/ enterohepatic recirculation. Reduced enterohepatic recirculation w/ cyclosporine A. Decreased MPA exposure w/ rifampin, norfloxacin & metronidazole. Decreased MPA plasma conc w/ sevelamer. Elevated MPA trough plasma conc w/ tacrolimus & sirolimus. Reduced pre-dose (trough) MPA conc w/ ciprofloxacin & amoxicillin plus clavulanic acid. Decrease plasma conc of levonogestrel. Live vaccines. Raised plasma AUC w/ probenecid.
MIMS Class
ATC Classification
L04AA06 - mycophenolic acid ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.
Immucept 250 cap 250 mg
10 × 10's
Immucept 500 tab 500 mg
5 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in